Home / Work / Graphic + Traditional Design / Genentech
Genentech
Strategic Footprint & Brand Integration
OVERVIEW:
Founded in 1976 and a member of the Roche Group, Genentech is a biotechnology pioneer credited with launching the first targeted therapies for life-threatening diseases. Headquartered in South San Francisco, the company is globally recognized for its rigorous scientific research and its commitment to developing medicines for oncology, immunology, and rare respiratory conditions. For decades, Genentech has set the industry standard for both medical innovation and high-science brand identity.
ROLES:
Graphic & Visual Design
Print Design
INSIGHT:
At the time of this initiative, GSW Worldwide sought to deepen its strategic partnership with Genentech by expanding into new business silos.
Having already established a successful track record with key products—including Nutropin (growth hormone), Pulmozyme (cystic fibrosis), and Raptiva (immunology)—the agency aimed to leverage this multi-drug experience as a proof of concept. The goal was to transition from being a product-specific vendor to a portfolio-wide strategic partner, demonstrating an intimate understanding of Genentech’s unique corporate culture and patient-centric approach.
OBJECTIVE:
The primary objective was to design high-impact print collateral for a major business development presentation that would secure this expanded partnership.
My role focused on creating a cohesive visual narrative that bridged the gap between Genentech’s technical, data-driven science and GSW’s creative marketing vision. This involved developing bespoke brochures and presentation materials that adhered to strict regulatory standards while maintaining a sophisticated, modern aesthetic that resonated with Genentech’s high-level stakeholders.
RESULTS:
The presentation was successful in reinforcing the agency’s value proposition, resulting in the continued retention of Genentech as a key client. By showcasing a deep familiarity with their existing product line—from respiratory to endocrine therapies—the collateral proved that GSW was equipped to scale with the brand's evolving pipeline.
This effort contributed to a period of sustained partnership and trust, further solidifying GSW Worldwide’s "footprint" within the Genentech organization.
